Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer-a Population-based Cohort Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Oct 12

PMID 23056335

Citations 7

Authors

Maria E C Sandberg

Per Hall

Mikael Hartman

Anna L V Johansson

Sandra Eloranta

Alexander Ploner

Kamila Czene

Affiliations

Soon will be listed here.

Abstract

Background: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated with risk of metachronous (non-simultaneous) contralateral breast cancer (CBC), and to what extent endocrine therapy affects this association.

Methods: We studied the effect of ER-status of the first cancer on the risk of CBC overall, and for different ER-subtypes of CBC, using a large, population-based cohort. The cohort consisted of all women diagnosed with breast cancer in the Stockholm region 1976-2005; 25715 patients, of whom 940 suffered CBC. The relative risk was analyzed mainly using standardized incidence ratios (SIR).

Results: Women with breast cancer had a doubled risk of CBC compared to the risk of breast cancer in the general female population (SIR: 2.22 [2.08-2.36]), for women with a previous ER-positive cancer: SIR=2.30 (95% CI:2.11-2.50) and for women with a previous ER-negative cancer: SIR=2.17 (95% CI:1.82-2.55). The relative risk of ER-positive and ER-negative CBC was very similar for women with ER-positive first cancer (SIR=2.02 [95%CI: 1.80-2.27] and SIR=1.89 [95%CI: 1.46-2.41] respectively) while for patients with ER-negative first cancer the relative risk was significantly different (SIR=1.27 [95% CI:0.94-1.68] for ER-positive CBC and SIR=4.96 [95%CI:3.67-6.56] for ER-negative CBC). Patients with ER-positive first cancer who received hormone therapy still had a significantly higher risk of CBC than the risk of breast cancer for the general female population (SIR=1.74 [95% CI:1.47-2.03]).

Conclusion: The risk of CBC for a breast cancer patient is increased to about two-fold, compared to the risk of breast cancer in the general female population. This excess risk decreases, but does not disappear, with adjuvant endocrine therapy. Patients with ER-positive first cancers have an increased risk for CBC of both ER subtypes, while patients with ER-negative first cancer have a specifically increased risk of ER-negative CBC.

Citing Articles

Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study.

Ramin C, Mullooly M, Schonfeld S, Advani P, Bodelon C, Gierach G Cancer Causes Control. 2021; 32(8):803-813.

PMID: 33877513 PMC: 8499045. DOI: 10.1007/s10552-021-01432-2.

Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.

Reiner A, Lynch C, Sisti J, John E, Brooks J, Bernstein L Breast Cancer Res. 2017; 19(1):83.

PMID: 28724391 PMC: 5517810. DOI: 10.1186/s13058-017-0874-x.

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.

Prater J, Valeri F, Korol D, Rohrmann S, Dehler S J Cancer Res Clin Oncol. 2015; 142(2):365-71.

PMID: 26298838 DOI: 10.1007/s00432-015-2031-1.

Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.

Rusner C, Wolf K, Bandemer-Greulich U, Engel J, Stegmaier C, Holleczek B Breast Cancer Res. 2014; 16(5):452.

PMID: 25277819 PMC: 4303131. DOI: 10.1186/s13058-014-0452-4.

The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.

McVeigh T, Hughes L, Miller N, Sheehan M, Keane M, Sweeney K Eur J Cancer. 2014; 50(16):2763-70.

PMID: 25240289 PMC: 4204201. DOI: 10.1016/j.ejca.2014.08.002.

References

Vichapat V, Gillett C, Fentiman I, Tutt A, Holmberg L, Luchtenborg M . Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer. 2011; 47(13):1919-27. DOI: 10.1016/j.ejca.2011.05.004. View

Kurian A, McClure L, John E, Horn-Ross P, Ford J, Clarke C . Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009; 101(15):1058-65. PMC: 2720990. DOI: 10.1093/jnci/djp181. View

Sandberg M, Hartman M, Edgren G, Eloranta S, Ploner A, Hall P . Diagnostic work-up of contralateral breast cancers has not improved over calendar period. Breast Cancer Res Treat. 2010; 122(3):889-95. DOI: 10.1007/s10549-010-0748-8. View

Fisher B, Jeong J, Bryant J, Anderson S, Dignam J, Fisher E . Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004; 364(9437):858-68. DOI: 10.1016/S0140-6736(04)16981-X. View

Mariani L, Coradini D, Biganzoli E, Boracchi P, Marubini E, Pilotti S . Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat. 1997; 44(2):167-78. DOI: 10.1023/a:1005765403093. View

Jobsen J, van der Palen J, Ong F, Meerwaldt J . Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 2003; 12(2):83-8. DOI: 10.1016/s0960-9776(02)00278-3. View

Horn P, Thompson W . Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer. 1988; 62(2):412-24. DOI: 10.1002/1097-0142(19880715)62:2<412::aid-cncr2820620228>3.0.co;2-3. View

Ma H, Bernstein L, Pike M, Ursin G . Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006; 8(4):R43. PMC: 1779465. DOI: 10.1186/bcr1525. View

Li C, Malone K, Weiss N, Daling J . Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001; 93(13):1008-13. DOI: 10.1093/jnci/93.13.1008. View

10.

Althuis M, Fergenbaum J, Garcia-Closas M, Brinton L, Madigan M, Sherman M . Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004; 13(10):1558-68. View

11.

Khoshnoud M, Lofdahl B, Fohlin H, Fornander T, Stal O, Skoog L . Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat. 2010; 126(2):421-30. DOI: 10.1007/s10549-010-1202-7. View

12.

Hungness E, Safa M, Shaughnessy E, ARON B, Gazder P, Hawkins H . Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery. 2000; 128(4):702-7. DOI: 10.1067/msy.2000.108780. View

13.

Greene G, Nolan C, Engler J, JENSEN E . Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci U S A. 1980; 77(9):5115-9. PMC: 350007. DOI: 10.1073/pnas.77.9.5115. View

14.

Adami H, Bergstrom R, Hansen J . Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer. 1985; 55(3):643-7. DOI: 10.1002/1097-0142(19850201)55:3<643::aid-cncr2820550328>3.0.co;2-l. View

15.

Hankey B, Curtis R, Naughton M, Boice Jr J, Flannery J . A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst. 1983; 70(5):797-804. View

16.

Healey E, Cook E, Orav E, Schnitt S, Connolly J, Harris J . Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993; 11(8):1545-52. DOI: 10.1200/JCO.1993.11.8.1545. View

17.

Teraoka S, Bernstein J, Reiner A, Haile R, Bernstein L, Lynch C . Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res. 2011; 13(6):R114. PMC: 3326556. DOI: 10.1186/bcr3057. View

18.

Chen Y, Thompson W, Semenciw R, Mao Y . Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8(10):855-61. View

19.

Nichols H, Berrington de Gonzalez A, Lacey Jr J, Rosenberg P, Anderson W . Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011; 29(12):1564-9. PMC: 3082975. DOI: 10.1200/JCO.2010.32.7395. View

20.

Wrange O, Nordenskjold B, Gustafsson J . Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem. 1978; 85(2):461-75. DOI: 10.1016/0003-2697(78)90243-9. View